Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Melpomeni Fani is active.

Publication


Featured researches published by Melpomeni Fani.


European Journal of Nuclear Medicine and Molecular Imaging | 2011

[68Ga]NODAGA-RGD for imaging αvβ3 integrin expression

Peter A. Knetsch; Milos Petrik; Christoph M. Griessinger; Christine Rangger; Melpomeni Fani; Christian Kesenheimer; Elisabeth von Guggenberg; Bernd J. Pichler; Irene Virgolini; Clemens Decristoforo; Roland Haubner

PurposeA molecular target involved in the angiogenic process is the αvβ3 integrin. It has been demonstrated in preclinical as well as in clinical studies that radiolabelled RGD peptides and positron emission tomography (PET) allow noninvasive monitoring of αvβ3 expression. Here we introduce a 68Ga-labelled NOTA-conjugated RGD peptide ([68Ga]NODAGA-RGD) and compare its imaging properties with [68Ga]DOTA-RGD using small animal PET.MethodsSynthesis of c(RGDfK(NODAGA)) was based on solid phase peptide synthesis protocols using the Fmoc strategy. The 68Ga labelling protocol was optimized concerning temperature, peptide concentration and reaction time. For in vitro characterization, partition coefficient, protein binding properties, serum stability, αvβ3 binding affinity and cell uptake were determined. To characterize the in vivo properties, biodistribution studies and microPET imaging were carried out. For both in vitro and in vivo evaluation, αvβ3-positive human melanoma M21 and αvβ3-negative M21-L cells were used.Results[68Ga]NODAGA-RGD can be produced within 5xa0min at room temperature with high radiochemical yield and purity (> 96%). In vitro evaluation showed high αvβ3 binding affinity (IC50u2009=u20094.7u2009±u20091.6xa0nM) and receptor-specific uptake. The radiotracer was stable in phosphate-buffered saline, pH 7.4, FeCl3 solution, and human serum. Protein-bound activity after 180xa0min incubation was found to be 12-fold lower than for [68Ga]DOTA-RGD. Biodistribution data 60xa0min post-injection confirmed receptor-specific tumour accumulation. The activity concentration of [68Ga]NODAGA-RGD was lower than [68Ga]DOTA-RGD in all organs and tissues investigated, leading to an improved tumour to blood ratio ([68Ga]NODAGA-RGD: 11, [68Ga]DOTA-RGD: 4). MicroPET imaging confirmed the improved imaging properties of [68Ga]NODAGA-RGD compared to [68Ga]DOTA-RGD.ConclusionThe introduced [68Ga]NODAGA-RGD combines easy accessibility with high stability and good imaging properties making it an interesting alternative to the 18F-labelled RGD peptides currently used for imaging αvβ3 expression.


Blood | 2013

Inflammatory neovascularization during graft-versus-host disease is regulated by αv integrin and miR-100

Franziska Leonhardt; Sebastian Grundmann; Martin Behe; Franziska Bluhm; Rebecca A. Dumont; Friederike Braun; Melpomeni Fani; Katarina Riesner; Gabriele Prinz; Anne-Kathrin Hechinger; Ulrike V. Gerlach; Heide Dierbach; Olaf Penack; Annette Schmitt-Gräff; Jürgen Finke; Wolfgang A. Weber; Robert Zeiser

Acute graft-versus-host disease (GvHD) is a complex process involving endothelial damage and neovascularization. Better understanding of the pathophysiology of neovascularization during GvHD could help to target this process while leaving T-cell function intact. Under ischemic conditions, neovascularization is regulated by different micro RNAs (miRs), which potentially play a role in inflamed hypoxic GvHD target organs. We observed strong neovascularization in the murine inflamed intestinal tract (IT) during GvHD. Positron emission tomography imaging demonstrated abundant αvβ3 integrin expression within intestinal neovascularization areas. To interfere with neovascularization, we targeted αv integrin-expressing endothelial cells, which blocked their accumulation in the IT and reduced GvHD severity independent of immune reconstitution and graft-versus-tumor effects. Additionally, enhanced neovascularization and αv integrin expression correlated with GvHD severity in humans. Expression analysis of miRs in the inflamed IT of mice developing GvHD identified miR-100 as significantly downregulated. Inactivation of miR-100 enhanced GvHD indicating a protective role for miR-100 via blocking inflammatory neovascularization. Our data from the mouse model and patients indicate that inflammatory neovascularization is a central event during intestinal GvHD that can be inhibited by targeting αv integrin. We identify negative regulation of GvHD-related neovascularization by miR-100, which indicates common pathomechanistic features of GvHD and ischemia.


18th European Congress of Endocrinology | 2016

Glucagon-like-1 Receptor imaging specifically localizes insulinomas in patients with Multiple Endocrine Neoplasia Type 1 (MEN-1)

Kwadwo Antwi; Melpomeni Fani; Tobias Heye; Guillaume Nicolas; Elmar M. Merkle; François Pattou; Ashley Grossmann; Philippe Chanson; Jean Claude Reubi; Beat Gloor; Damian Wild; Emanuel Christ


The Journal of Nuclear Medicine | 2012

Use of 68Ga-DOTA-TATE PET/CT for predicting the dose of 177Lu-DOTA-TATE therapy in patients with neuroendocrine tumors (NETs)

Simone Scheler; Richard Fischer; Melpomeni Fani; Helmut Maecke; Wolfgang A. Weber; Damian Wild


18th European Congress of Endocrinology | 2016

Localization of benign insulinomas using glucagon-like peptide-1 receptor (GLP1-R) SPECT/CT and PET/CT and MRI in a prospective clinical study

Kwadwo Antwi; Melpomeni Fani; Tobias Heye; Guillaume Nicolas; Elmar M. Merkle; Jean Claude Reubi; Beat Gloor; Damian Wild; Emanuel Christ


17th European Congress of Endocrinology | 2015

Localisation of insulinoma: comparison of glucagon-like peptide 1 receptor SPECT/CT, PET/CT, and MRI: preliminary results of a prospective clinical study

Kwadwo Antwi; Melpomeni Fani; Tobias Heye; Guillaume Nicolas; Elmar M. Merkle; Jean Claude Reubi; Beat Gloor; Stefan Fischli; Damian Wild; Emanuel Christ


Society of Nuclear Medicine Annual Meeting Abstracts | 2013

Monitoring bevacizumab therapy with PET/CT and 68Ga-NODAGA-c(RGDfK)

Svetlana N. Rylova; Enikö Barnucz; Melpomeni Fani; Friederike Braun; Yvonne Kiefer; Roswitha Toennesmann; Martin Werner; Silke Lassmann; Wolfgang Weber


Society of Nuclear Medicine Annual Meeting Abstracts | 2012

Unexpected sensitivity of SST2 antagonists to radiometal modifications

Helmut Maecke; Melpomeni Fani; Friederike Braun; Judit Erchegyi; Wolfgang Weber; Jean Edouard Frederic Rivier; Jean Claude Reubi; Beatrice Waser; Renzo Cescato


Society of Nuclear Medicine Annual Meeting Abstracts | 2012

Development of potent somatostatin antagonists for translational nuclear imaging of GRPr-positive tumor

Xuejuan Wang; Melpomeni Fani; Helmut Maecke


Society of Nuclear Medicine Annual Meeting Abstracts | 2012

Comprehensive evaluation of a somatostatin-based radiolabeled antagonist for diagnostic imaging and radionuclide therapy

Xuejuan Wang; Melpomeni Fani; Jean Claude Reubi; Helmut Maecke

Collaboration


Dive into the Melpomeni Fani's collaboration.

Top Co-Authors

Avatar

Jean Claude Reubi

University of Texas Health Science Center at Houston

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Wolfgang Weber

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tobias Heye

University Hospital Heidelberg

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge